Results 71 to 80 of about 429 (97)

Mature tertiary lymphoid structures linked to HPV status and anti-PD-1 based chemoimmunotherapy response in head and neck squamous cell carcinoma. [PDF]

Oncoimmunology
Zhang L, Ren S, Lan T, Marco V, Liu N, Wei B, Chen Y, Wu J, Li Q, Wu F, Lu P, Miao J, Lin H, Wang X, Zhong J, Li J, Fan S.   +16 more
europepmc   +1 more source

Interobserver reproducibility of cervical histology interpretation with and without p16 immunohistochemistry. [PDF]

Am J Clin Pathol
Tao AS, Zuna R, Darragh TM, Grabe N, Lahrmann B, Clarke MA, Wentzensen N.   +6 more
europepmc   +1 more source

Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial). [PDF]

ESMO Open
Hwang S, Hong MH, Shin SH, Yun T, Lee KW, Kim JH, Ahn MJ, Keam B, Lee HW, Kim MK, Yun HJ, Kim Y, Kim HJ, Cho SH, An HJ, Oh SY, Park SG, Koh YW, Ahn HK, Kwon JH, Lee YG, Park KU, Hwang IG, Kim SB, Kim S, Kim HR, KCSG TRIUMPH investigators.   +26 more
europepmc   +1 more source

Impact of differentiating between persistent and new infections on colposcopy referral in HPV-positive triage-negative women: results from the NTCC2 study. [PDF]

Infect Agent Cancer
Del Mistro A, Mancuso P, Carozzi F, De Marco L, Bisanzi S, Pompeo G, Ronco G, Gori S, Allia E, Gustinucci D, Frayle H, Iossa A, Cesarini E, Bulletti S, Passamonti B, Viti J, Toniolo L, Venturelli F, Giorgi Rossi P, Benevolo M, NTCC2 Working Group.   +20 more
europepmc   +1 more source

Evaluation of an HPV16-L1 antibody rapid test for oropharyngeal cancer diagnosis: diagnostic accuracy and challenges in real-world settings. [PDF]

EBioMedicine
Kusters JMA, Brenner N, Bogaards JA, Silling S, El-Zein M, Gray P, Kann H, Franco EL, Lehtinen M, Dietz A, Laban S, Klussmann JP, Wieland U, Waterboer T.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Cancer Cell, 2022
Zi-Xian Wang, Yun Fan, Lin Shen
exaly  

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

Lancet, The, 2021
Christopher J Sweeney Mbbs, Sergio Bracarda, Cora N Sternberg   +2 more
exaly  

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Lancet, The, 2021
Jong-Mu Sun, Manish A Shah, Toshihiko Doi   +2 more
exaly